T. Rowe Price Associates, Inc. 13D and 13G filings for C4 Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 1:22 pm Sale |
2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC |
T. Rowe Price Associates, Inc. | 392,004 0.600% |
-2,166,476 (-84.68%) |
Filing |
| 2024-02-14 10:03 am Sale |
2023-12-31 | 13G | C4 Therapeutics, Inc. CCCC |
T. Rowe Price Associates, Inc. | 2,558,480 5.200% |
-366,773 (-12.54%) |
Filing |
| 2023-02-14 12:38 pm Sale |
2022-12-31 | 13G | C4 Therapeutics, Inc. CCCC |
T. Rowe Price Associates, Inc. | 2,925,253 6.000% |
-1,159,545 (-28.39%) |
Filing |
| 2022-02-14 2:34 pm Purchase |
2021-12-31 | 13G | C4 Therapeutics, Inc. CCCC |
T. Rowe Price Associates, Inc. | 4,084,798 8.400% |
4,084,798 (New Position) |
Filing |